Intratumoral CAN2109 in Subjects With Solid Tumors

Exclusion Criteria

• •1. Unresolved toxicities from prior therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5.0) Grade 0 or 1, with exception of endocrinopathies from prior therapy, alopecia, and vitiligo.
• •2. Treatment with systemic corticosteroids at doses exceeding 10 mg/day prednisone or equivalent.
• •3. Has an active infection requiring systemic therapy.
• •4. Unstable/inadequate cardiac function defined as follows:
• •1. New York Heart Association Class 3 or 4 congestive heart failure
• •2. uncontrolled hypertension
• •3. acute coronary syndrome within 6 months
• •4. clinical important cardiac arrhythmia
• •5. mean corrected QT (QTc) interval corrected for heart rate \> 480 ms.
• •5. A history of interstitial lung disease.
• •6. A history of coagulopathy resulting in uncontrolled bleeding or other bleeding disorders.
• •7. Participated in a clinical study of an investigational agent within 30 days of screening.
• •8. Has known psychiatric, substance abuse, or other disorders that would interfere with cooperation with the requirements of the study in the opinion of the investigator.
• •9. Is pregnant or breastfeeding.